JP7769605B2 - リファブチン処置法、使用および組成物 - Google Patents

リファブチン処置法、使用および組成物

Info

Publication number
JP7769605B2
JP7769605B2 JP2022516161A JP2022516161A JP7769605B2 JP 7769605 B2 JP7769605 B2 JP 7769605B2 JP 2022516161 A JP2022516161 A JP 2022516161A JP 2022516161 A JP2022516161 A JP 2022516161A JP 7769605 B2 JP7769605 B2 JP 7769605B2
Authority
JP
Japan
Prior art keywords
rifabutin
composition
baumannii
solvent
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022516161A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548252A (ja
Inventor
グレン エー． ダーレ，
セルジオ ロチューロ，
クリスティアン ケンマー，
ヴァンサン トレボスク，
マルク ギッツィンガー，
Original Assignee
バイオバーシズ アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオバーシズ アーゲー filed Critical バイオバーシズ アーゲー
Publication of JP2022548252A publication Critical patent/JP2022548252A/ja
Priority to JP2025184422A priority Critical patent/JP2026016690A/ja
Application granted granted Critical
Publication of JP7769605B2 publication Critical patent/JP7769605B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022516161A 2019-09-12 2020-08-03 リファブチン処置法、使用および組成物 Active JP7769605B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025184422A JP2026016690A (ja) 2019-09-12 2025-10-31 リファブチン処置法、使用および組成物

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962899257P 2019-09-12 2019-09-12
US62/899,257 2019-09-12
US201962902019P 2019-09-18 2019-09-18
US62/902,019 2019-09-18
US201962941160P 2019-11-27 2019-11-27
US62/941,160 2019-11-27
US202062977659P 2020-02-17 2020-02-17
US62/977,659 2020-02-17
PCT/IB2020/000647 WO2021048611A1 (en) 2019-09-12 2020-08-03 Rifabutin treatment methods, uses, and compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025184422A Division JP2026016690A (ja) 2019-09-12 2025-10-31 リファブチン処置法、使用および組成物

Publications (2)

Publication Number Publication Date
JP2022548252A JP2022548252A (ja) 2022-11-17
JP7769605B2 true JP7769605B2 (ja) 2025-11-13

Family

ID=72432957

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2022516161A Active JP7769605B2 (ja) 2019-09-12 2020-08-03 リファブチン処置法、使用および組成物
JP2022516163A Active JP7804570B2 (ja) 2019-09-12 2020-08-03 抗生物質併用療法
JP2025145104A Pending JP2025176113A (ja) 2019-09-12 2025-09-02 抗生物質併用療法
JP2025184422A Pending JP2026016690A (ja) 2019-09-12 2025-10-31 リファブチン処置法、使用および組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022516163A Active JP7804570B2 (ja) 2019-09-12 2020-08-03 抗生物質併用療法
JP2025145104A Pending JP2025176113A (ja) 2019-09-12 2025-09-02 抗生物質併用療法
JP2025184422A Pending JP2026016690A (ja) 2019-09-12 2025-10-31 リファブチン処置法、使用および組成物

Country Status (17)

Country Link
US (6) US11207305B2 (https=)
EP (3) EP4028001B1 (https=)
JP (4) JP7769605B2 (https=)
KR (1) KR20220103698A (https=)
CN (3) CN115052597B (https=)
AU (2) AU2020344214B2 (https=)
BR (2) BR112022004672A2 (https=)
CA (2) CA3154317A1 (https=)
ES (1) ES2982067T3 (https=)
HR (1) HRP20240818T1 (https=)
HU (1) HUE066936T2 (https=)
MX (1) MX2022003077A (https=)
PH (1) PH12022550610A1 (https=)
PL (1) PL4028001T3 (https=)
RS (1) RS65681B1 (https=)
SM (1) SMT202400250T1 (https=)
WO (2) WO2021048610A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230364065A1 (en) * 2022-05-16 2023-11-16 BioVersys AG Antibiotic combination therapies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645508B1 (en) * 1999-06-18 2003-11-11 Jivn-Ren Chen Stable L-ascorbic acid composition
CN101362067A (zh) * 2007-08-06 2009-02-11 天津科技大学 一种微胶囊制备方法
PT2247291T (pt) * 2008-02-08 2019-02-01 Red Hill Biopharma Ltd Métodos e composições para tratamento de doença inflamatória do intestino
MY158809A (en) 2010-09-22 2016-11-15 Craun Res Sdn Bhd Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
EA016410B1 (ru) 2010-11-13 2012-04-30 Ооо "Нпк Наносистема" Фармацевтическая композиция на основе наночастиц циклодекстрина, содержащих рифабутин, способ ее получения, способ лечения микобактериоза и геликобактерной инфекции (варианты)
US10064858B2 (en) * 2011-01-31 2018-09-04 The United States Of America, As Represented By The Secretary Of The Army Methods and compositions for treating bacterial infections with iron chelators
CN102178604B (zh) 2011-03-22 2014-03-05 中国人民解放军第三0九医院 凝胶微球制备装置、方法及可注射抗结核药物凝胶微球
RU2472512C1 (ru) * 2011-12-06 2013-01-20 Общество С Ограниченной Ответственностью "Ибмх-Экобиофарм" Противотуберкулезная композиция и способ ее получения
WO2016013986A1 (en) * 2014-07-25 2016-01-28 Agency For Science, Technology And Research Antibiotic compositions for treating bacterial infections
CN107148479A (zh) * 2014-09-04 2017-09-08 赛拉诺斯股份有限公司 病原体和抗微生物剂抗性检测
US9763996B2 (en) 2015-01-16 2017-09-19 Northern Antibiotics, Ltd. Polymyxin derivative and uses thereof
EP3291798A4 (en) * 2015-05-04 2019-01-16 Gufic Biosciences Limited FREEZE-DRIED PHARMACEUTICAL FORMULATION OF RIFABUTIN AND METHOD FOR THE PRODUCTION THEREOF
JP7072898B2 (ja) * 2016-08-16 2022-05-23 ユニバーシティ オブ ロチェスター ポリミキシンｂ／トリメトプリム系の治療薬を含有する医薬組成物
JP2020506236A (ja) 2017-02-07 2020-02-27 エスティーシー． ユーエヌエムＳｔｃ．Ｕｎｍ 長期間持続するオートファジー誘発のための同位体増強アンブロキソール
US11701346B2 (en) * 2018-11-28 2023-07-18 University Of Southern California Rifabutin for the treatment of acinetobacter baumannii

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SUN, W. et al.，Emerging Microbes & Infections，2016年11月09日，Vol.5, Issue 11, Article:e116，pp.1-11.

Also Published As

Publication number Publication date
HRP20240818T1 (hr) 2024-10-11
EP4028001B1 (en) 2024-04-10
WO2021048610A1 (en) 2021-03-18
AU2020347536A1 (en) 2022-04-14
JP2026016690A (ja) 2026-02-03
KR20220103698A (ko) 2022-07-22
US20250281469A1 (en) 2025-09-11
PL4028001T3 (pl) 2024-07-22
CN115052597B (zh) 2025-07-08
AU2020344214A1 (en) 2022-04-21
US11833139B2 (en) 2023-12-05
CN120860031A (zh) 2025-10-31
JP2022548252A (ja) 2022-11-17
US20220184048A1 (en) 2022-06-16
BR112022004672A2 (pt) 2022-06-07
EP4028001C0 (en) 2024-04-10
US11351158B2 (en) 2022-06-07
CN114980889A (zh) 2022-08-30
ES2982067T3 (es) 2024-10-14
WO2021048611A1 (en) 2021-03-18
JP2025176113A (ja) 2025-12-03
BR112022004645A2 (pt) 2022-06-21
EP4028000A1 (en) 2022-07-20
SMT202400250T1 (it) 2024-07-09
AU2020347536B2 (en) 2025-09-25
JP7804570B2 (ja) 2026-01-22
MX2022003077A (es) 2022-07-11
US11207305B2 (en) 2021-12-28
CA3154317A1 (en) 2021-03-18
RS65681B1 (sr) 2024-07-31
US20230132691A1 (en) 2023-05-04
US11766425B2 (en) 2023-09-26
US12257241B2 (en) 2025-03-25
CN115052597A (zh) 2022-09-13
US20210077472A1 (en) 2021-03-18
EP4420673A2 (en) 2024-08-28
CA3154129A1 (en) 2021-03-18
US20210077471A1 (en) 2021-03-18
JP2022551228A (ja) 2022-12-08
EP4420673A3 (en) 2024-11-06
AU2020344214B2 (en) 2026-01-22
HUE066936T2 (hu) 2024-09-28
PH12022550610A1 (en) 2023-03-13
US20240041845A1 (en) 2024-02-08
EP4028001A1 (en) 2022-07-20

Similar Documents

Publication Publication Date Title
Ducarmon et al. Gut microbiota and colonization resistance against bacterial enteric infection
Hurst et al. Levofloxacin: an updated review of its use in the treatment of bacterial infections
Estes et al. Present and future therapeutic strategies for melioidosis and glanders
Baucheron et al. TolC but not AcrB is essential for multidrug-resistant Salmonella enterica serotype Typhimurium colonization of chicks
JP2026016690A (ja) リファブチン処置法、使用および組成物
CN112218659A (zh) 用于治疗葡萄球菌感染的治疗性噬菌体组合物
US20230381157A1 (en) Rifabutin for the treatment of acinetobacter baumannii
WO2014080378A1 (en) Phenothiazine derivatives and their use against tuberculosis
CN115943141A (zh) 施用他非诺喹治疗和预防肺部感染的方法
JP2022539583A (ja) マイコプラズマ・ジェニタリウムによって引き起こされる感染症の治療のための組合せ
HK40115867A (en) Rifabutin treatment methods, uses, and compositions
CN110087655A (zh) 9-氨基甲基米诺环素化合物及其在治疗社区获得性细菌性肺炎(cabp)中的用途
US20190201479A1 (en) Treating infections using idsd from proteus mirabilis
Rao et al. Targeting mycobacterial efflux system to enhance tuberculosis therapy
CN115089699B (zh) Apo-E模拟肽COG1410在制备抑制分枝杆菌药物中的应用
CN102138917A (zh) 二甲基黄青霉素在制备抗结核药物中的应用
Cole et al. Highlights from the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
WO2001021176A1 (en) Methods of use of fluoroquinolone compounds against bacteria
CN106890167A (zh) 一种具有抗结核活性的化合物及其应用
Pearce et al. Inhalational antibiotic therapy for treatment of chronic pulmonary Mycobacterium abscessus disease in mice
Castañeda-Meléndrez et al. Genomic characterization of a multidrug-resistant uropathogenic Escherichia coli and evaluation of Echeveria plant extracts as antibacterials
KR20230085579A (ko) 항병원성 활성 및 바이오필름 형성 억제 효과를 나타내는 화합물의 신규한 용도
WO2026011445A1 (zh) Kl2型鲍曼不动杆菌噬菌体及其筛选方法、噬菌体组合物及应用与药物
Foca et al. Rational treatment of pulmonary infections in patients with cystic fibrosis
WO2018070874A1 (en) Means and methods for reducing or avoiding antibiotic resistance and spread of virulence in human pathogens

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230803

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240801

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250430

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250904

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251001

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251031

R150 Certificate of patent or registration of utility model

Ref document number: 7769605

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150